Skip to main content
Premium Trial:

Request an Annual Quote

Monsanto Licenses Resolver Expression Analysis System from Rosetta

NEW YORK, June 27 - Monsanto has licensed the Rosetta Resolver gene expression data analysis system from Rosetta Inpharmatics, Rosetta said Wednesday. 

Financial details of the transaction were not disclosed. The Resolver system, Rosetta's flagship product, is exclusively distributed by Agilent Technologies, based in Palo Alto, Calif.

In May, Merck acquired Rosetta for $620 million in stock, but said that Rosetta would continue to operate the Resolver business as a separate cost center. Rosetta has licensed its Resolver system to a number of pharmaceutical and biotechnology companies, including GlaxoSmithKline, Biogen, Immunex, Paradigm Genetics, and Merck.

The Resolver system accepts data from a wide variety of expression profiling formats, including Affymetrix GeneChip and Agilent DNA microarrays, and applies proprietary error models to calculate statistics on the gene expression data. Rosetta, based in Kirkland, Wash., released version 2.0 of the system in the first quarter of 2001.

"The Rosetta Resolver system, which will empower us to conduct thorough and rapid analysis of our gene expression data, has comprehensive features and high quality statistics that can help us to quickly and efficiently develop products and solutions to achieve our goal," said Christine Karslake, director of business development for Monsanto, in a statement.  
The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.